<DOC>
	<DOCNO>NCT01076452</DOCNO>
	<brief_summary>The goal second phase study determine simultaneous bilateral subthalamic nucleus stimulation simultaneous bilateral globus pallidus stimulation effective reducing symptom Parkinson 's Disease .</brief_summary>
	<brief_title>Phase II Subthalamic Nucleus ( STN ) vs. Globus Pallidus ( GPi ) Trial</brief_title>
	<detailed_description>Deep Brain Stimulation ( DBS ) promise therapy Parkinson 's disease ( PD ) Whether DBS superior comprehensive best medical therapy whether patient symptom respond good DBS one area brain currently know . The goal project compare effectiveness DBS comprehensive medical therapy treatment PD ( Phase I ) compare bilateral DBS 2 area brain-the subthalamic nucleus ( STN ) globus pallidus ( GPi ) -to determine effective brain site surgical intervention ( Phase II ) In prospective , randomize , multi-center trial , 316 patient enrol 13 center four half year . Patients initially randomize immediate surgery ( DBS ) 6 month `` best medical therapy '' . BMT arm patient randomize proceed DBS surgical phase trial . The DBS site ( STN pr GPi ) assign random basis time patient enters surgical phase trial . Patients follow two year post surgery ( 24 month DBS patient 30 month BMT-DBS patient ) Effective 8/5/05 randomization BMT arm discontinue since study sufficient information compare outcomes DBS BMT patient 6 month . The finding critically important establish optimal surgical treatment disable symptom PD .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>idiopathic Parkinson 's Disease Hoehn Yahr stage 2 bad medication Ldopa responsive clearly define `` '' period ( i.e . symptom improve least partially Ldopa administration , characteristic help distinguish idiopathic PD `` Parkinson 's Plus '' atypical Parkinson 's syndromessee ) persistent disable symptom ( e.g . trouble dyskinesia , disable `` '' period least 3 hours/day ) despite medication therapy . Patients treat variable dos levodopa dopamine agonist ( minimum ) adequate trial adjunctive medication ) stable medical therapy least one month prior study enrollment age &gt; 21 available willing followedup accord study protocol `` Parkinson 's plus '' syndrome , secondary , atypical Parkinson 's syndrome ( e.g . progressive supranuclear palsy , striatonigral degeneration , multiple system atrophy , poststroke , posttraumatic , postencephalitic Parkinson 's . These patient cardinal symptom characteristic PD additional symptom indicate organic brain dysfunction , gaze palsy , autonomic dysfunction , lack response Ldopa , individual tend improve standard treatment PD ) previous Parkinson 's Disease surgery medical contraindication surgery stimulation ( e.g . uncontrolled hypertension , advance coronary artery disease , implanted stimulation electronicallycontrolled device include cardiac demand pacemaker , aneurysm clip , cochlear implant , spinal cord stimulator ) ( Note : subject receive either pacemaker and/or defibrillator study enrollment , he/she allow continue study neurostimulator system adequately program permit system compatibility ) contraindication magnetic resonance imaging ( e.g . indwell metal fragment implant might affect MRI ) active alcohol drug abuse score MiniMental Status examination 24 low , neuropsychological dysfunction 9e.g . dementia ) would contraindicate surgery intracranial abnormality would contraindicate surgery ( e.g . stroke , tumor , vascular abnormality affect target area ) pregnancy concurrent participation another research protocol</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>levo-dopa</keyword>
	<keyword>tremor</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>subthalamic nucleus</keyword>
	<keyword>globus pallidus</keyword>
</DOC>